As a tyrosine kinase inhibitor, it simultaneously suppresses VEGFR, PDGFR, and FGFR signaling pathways, effectively inhibiting tumor angiogenesis and disrupting stromal cell functions in the tumor microenvironment, thereby enhancing the local antitumor efficacy of radiotherapy (23). Here, PDGFRB is linked to neoplasm.